I agree that a model of care needs to be established for haemochromatosis patients that would provide equal access in the most cost-effective manner possible. In this regard the HSE's National Clinical Programme for Blood Transfusion has reviewed services nationally for haemochromatosis patients with a view to providing a service that reflects best international practice in terms of patient care and value for money. I understand that discussions are ongoing with the Irish Blood Transfusion Service and other relevant parties such as GPs to examine options for the improved care of haemochromatosis patients and I look forward to hearing the outcome of these discussions.